Ten-year results of the Multicentric Italian Lung Detection trial demonstrate the safety and efficacy of biennial lung cancer screening.
暂无分享,去创建一个
G. Corrao | U. Pastorino | M. Boeri | G. Sozzi | Mario Silva | N. Sverzellati | M. Silva | S. Sestini | F. Sabia | A. Cantarutti | A. Marchiano | G. Corrao
[1] C. Berg,et al. Identification of candidates for longer lung cancer screening intervals following a negative low-dose computed tomography result. , 2019, Journal of the National Cancer Institute.
[2] C. la Vecchia,et al. Efficacy of lung cancer screening appears to increase with prolonged intervention: results from the MILD trial and a meta-analysis. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] D. Aberle,et al. MILD trial, strong confirmation of lung cancer screening efficacy , 2019, Nature Reviews Clinical Oncology.
[4] G. Corrao,et al. Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] P. Massion,et al. Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[6] Bram van Ginneken,et al. Long‐Term Active Surveillance of Screening Detected Subsolid Nodules is a Safe Strategy to Reduce Overtreatment , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[7] M. Oudkerk,et al. PL02.05 Effects of Volume CT Lung Cancer Screening: Mortality Results of the NELSON Randomised-Controlled Population Based Trial , 2018, Journal of Thoracic Oncology.
[8] H. Kauczor,et al. Cost-utility analysis of a potential lung cancer screening program for a high-risk population in Germany: A modelling approach. , 2018, Lung cancer.
[9] B. van Ginneken,et al. Lung cancer risk to personalise annual and biennial follow-up computed tomography screening , 2018, Thorax.
[10] Harry J de Koning,et al. Disagreement of diameter and volume measurements for pulmonary nodule size estimation in CT lung cancer screening , 2017, Thorax.
[11] H. D. de Koning,et al. Risk stratification based on screening history: the NELSON lung cancer screening study , 2017, Thorax.
[12] D. Origgi,et al. Exposure to low dose computed tomography for lung cancer screening and risk of cancer: secondary analysis of trial data and risk-benefit analysis , 2017, British Medical Journal.
[13] A. Miller,et al. Biennial lung cancer screening in Canada with smoking cessation-outcomes and cost-effectiveness. , 2016, Lung cancer.
[14] P. V. van Ooijen,et al. Final screening round of the NELSON lung cancer screening trial: the effect of a 2.5-year screening interval , 2016, Thorax.
[15] B. Kramer,et al. Lung cancer incidence and mortality in National Lung Screening Trial participants who underwent low-dose CT prevalence screening: a retrospective cohort analysis of a randomised, multicentre, diagnostic screening trial. , 2016, The Lancet. Oncology.
[16] Lisa M. Schwartz,et al. Patients’ Knowledge, Beliefs, and Distress Associated with Detection and Evaluation of Incidental Pulmonary Nodules for Cancer: Results from a Multicenter Survey , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[17] Asger Dirksen,et al. Results of the Randomized Danish Lung Cancer Screening Trial with Focus on High-Risk Profiling. , 2016, American journal of respiratory and critical care medicine.
[18] U. Pastorino,et al. Low-dose computed tomography for lung cancer screening: comparison of performance between annual and biennial screen , 2016, European Radiology.
[19] M. Scorsetti,et al. Long-Term Follow-up Results of the DANTE Trial, a Randomized Study of Lung Cancer Screening with Spiral Computed Tomography. , 2015, American journal of respiratory and critical care medicine.
[20] Harry J de Koning,et al. Lung cancer probability in patients with CT-detected pulmonary nodules: a prespecified analysis of data from the NELSON trial of low-dose CT screening. , 2014, The Lancet. Oncology.
[21] C. la Vecchia,et al. Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] William Hazelton,et al. Benefits and Harms of Computed Tomography Lung Cancer Screening Strategies: A Comparative Modeling Study for the U.S. Preventive Services Task Force , 2014, Annals of Internal Medicine.
[23] Ugo Pastorino,et al. Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial , 2012, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.
[24] L. Walter,et al. Cancer screening in elderly patients: a framework for individualized decision making. , 2001, JAMA.
[25] H. D. de Koning,et al. Lung cancer screening: latest developments and unanswered questions. , 2016, The Lancet. Respiratory medicine.
[26] M. Oudkerk,et al. Computed tomographic characteristics of interval and post screen carcinomas in lung cancer screening , 2014, European Radiology.
[27] C. Gatsonis,et al. Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .